The U.S. Food and Drug Administration (FDA) introduced new measures aimed at reducing the time and cost of developing biosimilars — affordable alternatives to biologic medicines used in treating chronic and serious diseases.
In a newly released draft guidance titled “Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies,” the FDA has proposed simplified pathways for demonstrating biosimilarity. The update significantly reduces the requirement for comparative clinical efficacy trials, which have historically been both expensive and time-consuming.
The agency noted that such studies — averaging $24 million and spanning one to three years — often show limited sensitivity compared to advanced analytical testing methods. Under the new framework, biosimilar developers can now rely more heavily on scientific and analytical assessments, marking a decisive shift toward data-driven evaluations.
Reducing Barriers for Interchangeable Biosimilars
The FDA also plans to scale back the requirement for “switching studies” for biosimilars seeking interchangeability with their reference biologic drugs. These studies, which test whether patients can safely switch between products, have been cited as a major source of regulatory delays and confusion among patients and healthcare professionals. Under the updated guidance, the FDA no longer generally recommends such studies, aligning biosimilar development more closely with the streamlined processes used for generic drugs.
Biosimilars: A Key to Affordable Biologic Medicines
Biologic drugs account for only 5% of all prescriptions in the U.S., yet they represent 51% of total drug spending as of 2024. Despite the FDA having approved 76 biosimilars since 2015, their market share remains below 20%, compared with over 30,000 approved generic drugs.
Furthermore, only 10% of biologics expected to lose patent protection over the next decade currently have a biosimilar in development — underscoring the need for regulatory reform to accelerate competition and reduce costs. The Biologics Price Competition and Innovation Act (BPCIA) of 2010 established the biosimilar approval pathway to promote competition in biologic markets. The FDA emphasized that the new measures aim to expand biosimilar availability, foster market competition, and lower costs for patients.
Industry Leaders Applaud FDA’s Forward-Looking Approach
Industry experts have welcomed the FDA’s initiative as a transformative step for global biosimilar development. Commenting on the development, Sudarshan Jain, Secretary General of the Indian Pharmaceutical Alliance, stated, “The recent announcement by the USFDA and CMS is a welcome step that will accelerate biosimilar development and lower drug costs for patients. The simplification of interchangeability guidelines and approval pathways will create a more enabling environment for the industry to diversify in the large-molecule space.”
He further added that with nearly 130 approved biosimilars, India is well-positioned to drive this global shift. “Over the next seven years, the U.S. will see more than 55 blockbuster drugs lose exclusivity. India has long been a trusted partner in ensuring access to quality-assured, affordable medicines for American patients. These reforms will further strengthen the U.S.–India partnership and our shared goal of improving healthcare access and affordability,” Jain mentioned.
A Step Toward Greater Global Access
By aligning scientific standards and easing regulatory barriers, the FDA’s new approach has the potential to reshape the global biosimilar landscape, creating a more competitive, affordable, and innovation-driven biopharmaceutical ecosystem. As reported by expresspharma.in, the move not only accelerates development but also reinforces the shared commitment between regulators and industry leaders to expand patient access to life-saving biologic therapies worldwide.